Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
ACTIVE NOT RECRUITING
NCT02685605
PHASE3

Intraoperative Radiotherapy in Newly Diagnosed Glioblastoma Multiforme

Sponsor: Universitätsmedizin Mannheim

View on ClinicalTrials.gov

Summary

INTRAGO II resembles a multicentric, prospective, randomized, 2-arm, open-label clinical phase III trial which tests if the median progression-free survival (PFS) of patients with newly diagnosed glioblastoma multiforme (GBM) can be improved by the addition of intraoperative radiotherapy (IORT) to standard radiochemotherapy.

Official title: A Multicenter Randomized Phase III Trial on INTraoperative RAdiotherapy in Newly Diagnosed GliOblastoma Multiforme (INTRAGO II)

Key Details

Gender

All

Age Range

18 Years - 80 Years

Study Type

INTERVENTIONAL

Enrollment

314

Start Date

2016-12-09

Completion Date

2026-06

Last Updated

2025-10-14

Healthy Volunteers

No

Conditions

Interventions

PROCEDURE

Standard surgery

RADIATION

Intraoperative radiotherapy

Dose to applicator surface: 20-30 Gy; Carl Zeiss INTRABEAM System. IORT with a surface dose of 30 Gy is recommended.Should the proximity to any risk structure not allow to apply 30 Gy, a dose reduction by up to 10 Gy (resulting in a surface dose of 20 Gy) is allowed.

RADIATION

Radiochemotherapy

EBRT to 60 Gy plus 75 mg/m2/d temozolomide

DRUG

Temozolomide

Adjuvant chemotherapy with 150-200 mg/m2/d temozolomide per cycle (5/28 days).

Locations (19)

Barrow Neurological Institute (SJHMC)

Phoenix, Arizona, United States

Stritch School of Medicine Loyola University

Maywood, Illinois, United States

Long Island Jewish Medical Center, North Shore University Hospital

Lake Success, New York, United States

Lenox Hill Hospital, Hofstra Northwell School of Medicine

New York, New York, United States

West Virginia University

Morgantown, West Virginia, United States

Hospital Alemão Oswaldo Cruz

São Paulo, Brazil

Montreal Neurological Institute and Hospital

Montreal, Quebec, Canada

Beijing Tian Tan Hospital, Capital Medical University

Beijing, China

University Hospital Augsburg

Augsburg, Germany

Charité - Universitätsmedizin

Berlin, Germany

St. Georg Hospital

Leipzig, Germany

University Hospital Mannheim

Mannheim, Germany

Technical University of Munich (TUM), Department of Radiation Oncology

Munich, Germany

Klinikum Stuttgart

Stuttgart, Germany

Helios University Hospital Wuppertal

Wuppertal, Germany

Gangnam Severance Hospital, Yonsei University College of Medicine

Seoul, South Korea

Catalan Institute of Oncology (ICO)

Barcelona, Spain

Hospital Reina Sofia

Córdoba, Spain

The London Clinic

London, United Kingdom